Novogenia H1 FY26 operating loss narrows 4.1% to EUR 4.7 million; revenue falls 7% to EUR 25.7 million
Bitget2026/09/28 07:00- Novogenia revenue fell 7% to EUR 25.7 million in H1 2026.
- Operating loss narrowed 4.1% to EUR 4.7 million, after cost cuts; prior-year operating income had been lifted by one-off other income.
- Net result swung to a loss of EUR 2.1 million, versus profit a year earlier, after a weaker financial result.
- Cash and securities totaled EUR 39.8 million at June 30, 2026.
- CEO Daniel Wallerstorfer said core genetics and personalized health products improved; the group launched MGT Plus in the U.S. and began marketing Multi-Cancer Check.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The EU questions why a certain exchange continues to operate after being asked to exit
How Strategy keeps STRC near $100 while MSTR stock swings
WTI Crude Oil Drops Over 1.00% Today, Currently at $88.55 per Barrel
Summary of the Bank of Japan's September meeting opinions: Majority of members advocate for continued rate hikes, some call for acceleration.
The summary of the Bank of Japan's September meeting opinions shows that some policymakers believe it is necessary to accelerate interest rate hikes or bring rates closer to the central bank's "target" as soon as possible, increasing the likelihood of further rate hikes.
Crypto prices
More
